ROS THERAPEUTICS
OPTIMIZING THE TREATMENT EXPERIENCE FOR CHILDREN WITH JIA AND OTHER AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS
About us
ROS Therapeutics is a development stage pharmaceutical company committed to optimize the treatment experience and address unmet needs of children with Juvenile Idiopathic Arthritis (JIA) and other autoimmune and chronic inflammatory conditions through an innovative proprietary best-in-class orally delivered methotrexate therapy; Trexior™.
Methotrexate (MTX) is a cornerstone treatment for JIA, one of the most common childhood diseases as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults.
Since the early 90’ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies.
Several of the shortcomings of existing
methotrexate therapies, whether oral or injections, are sought overcome with Trexior.
News
March 01, 2021
October 5, 2020
July 01, 2021
Leadership
Hanne Damgaard Jensen
Chief Executive Officer,
Board Member
Ricki Boye
Board Member
Christian Gunni Pedersen
Chief Financial Officer
Morten Sandlykke
Board Member
Ulrik Spork
Co-founder, Chairman
CONTACT US
ROS Therapeutics ApS, Ole Maaløes vej 3, 2200 Copenhagen N, Denmark